CME online

in association with the 20th Annual World Congress on Insulin Resistance
Diabetes and Cardiovascular Disease -WCIRDC

NEW HORIZON IN THE MANAGEMENT OF DIABETES KIDNEY DISEASE

This is a CME Symposium Supported by an Educational Grant from Bayer
Provided By:

Administrated by::
This CME online educational activity is approved for a maximum of 1.50 AMA PRA Category 1 Credit(s). and ABIM MOC

Accreditation period: January 15, 2023 – January 15, 2024

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be mailed to you upon satisfactory completion of these documents.

NEW HORIZON IN THE MANAGEMENT OF DIABETES KIDNEY DISEASE
Agenda

Introduction & Pre CME Questions
Yehuda Handelsman, MD

CKD in Diabetes-Prevalence,Pathophysiology Impact on Cardiometabolic Diseases
Erin Michos, MD

Diagnosing DKD- screening, methodology role of Guidelines
Matthew Weir, MD

New Treatment Paradigm of DKD the Role of Non-Steroidal MRA
Peter Rossing, MD, DMSc

Panel Discussion - The Future is Here- Management of DKD
Panel: : Erin Michos, MD • Peter Rossing, MD, DMSc • Matthew Weir, MD
Moderator: Yehuda Handelsman, MD

Faculty

Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE Chair

Chair & Program Director, WCIRDC
Medical Director & Principal Investigator,
Metabolic Institute of America
Chair & Founder,
International Committee for Insulin Resistance
Chair & Founder, International Lipid Forum
Tarzana, California

Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC

Associate Professor of Medicine (Cardiology) and Epidemiology
Associate Director of Preventive Cardiology
Johns Hopkins University School of Medicine
Baltimore, Maryland


Matthew R. Weir, MD

Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

Peter Rossing, MD, DMSc

Professor Department of Clinical Medicine
University of Copenhagen
Steno Diabetes Center Copenhagen
Herlev, Denmark

Program Description

Diabetes along with HTN is the main cause of CKD ad well as of HF and ASCVD. DKD is the leading cause of end-stage renal disease (ESRD) and accounts for near 30% of direct medical costs for diabetes-related conditions
Until recently the management of CKD has been based on controlling HTN, hyperglycemia, lipids and blocking RAAS with ACE inhibitors or ARB. Still, being able to improve diabetes kidney disease has been suboptimal. Patients are often diagnosed late or not at all hence are provided with deficient management plan. In addition, recent CVOTs introduced newer medications like SGLT2i a non-steroidal MRA demonstrating an impact on CKD HF and ASCVD.
Addressing physicians’ gaps of knowledge, in this CME symposium we will explore the impact pf the prevalence, and pathophysiology of CKD on Cardiometabolic Diseases, highlight the contemporary approach to diagnosis and management of these complex patients with a focus on emerging treatments specifically on finerenone a nonsteroidal MRA, which is largely unknown to clinicians.




Learning Objectives

Upon completion of this symposium, participants should be able to:

  • Discuss DKD epidemiology and pathophysiologic interactions with diabetes, and cardiometabolic diseases • Discuss the current standards and timing of screaming and diagnosing CKD in diabetes
  • Compare and contrast the benefits and limitations of accepted treatments for CKD management, including RAAS blockade agents, first generation MRAs, and SGLT2 inhibitors
  • Evaluate the clinical outcomes of FIDELIO and FIGARO and implication on the role of nonsteroidal MRAs specifically finerenone in the optimal therapeutic regimens for the management of DKD

    • Target Audience

    This educational initiative is designed for endocrinologists, cardiologists, nephrologists, primary care physicians, internists, and other healthcare professionals interested in the Epidemiology, pathophysiology, prevention, and treatment of diabetes with CKD and prevention of related morbidity and mortality.

    CME Statement

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PES Inc. is accredited by the ACCME to provide continuing medical education for physicians.
    PESI, Inc, designated this live educational activity for a maximum of 1.50 AMA PRA Category 1 Credit(s).
    Physicians should only claim credit commensurate with the extent of their participation in the activity.